Project Grant R01CA315499
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $667K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Federal Cooperative Agreement Award Summary The National Cancer Institute (NCI) awarded a $525,013 Cooperative Agreement to The University of Texas MD Anderson Cancer Center, effective September 1, 2025 through August 31, 2030, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394). This award funds translational research to validate blood-based biomarkers for lung cancer risk assessment among individuals with no smoking history. The project will evaluate the predictive...
- The National Cancer Institute awarded MD Anderson Cancer Center $669,540 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to elucidate the roles of the CD24 ligand in early lung cancer development, immune evasion, and response to KRAS-targeted therapy. The research investigates CD24 signaling in KRAS-mutant lung adenocarcinomas (KM-LUADs), which account for approximately 30 percent of lung adenocarcinomas in lifetime smokers. Preliminary findings indicate CD24 elevation...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $1.361 million on September 19, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and test a family-centered lifestyle intervention for Black prostate cancer survivors and their caregivers. The award funds a randomized controlled trial of "Together Stronger," a program targeting physical activity and healthy eating among Black prostate cancer survivors and their...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $717,715 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a multi-ancestry genome-wide association study of mammographic density phenotypes and their genetic and nongenetic determinants in over 120,000 multiethnic women. The project addresses the genetic basis of mammographic density—a strong and common breast cancer risk factor that reduces screening...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $192,224 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research on secreted peptides as biomarkers and effectors of neuroendocrine transformation in lung cancer. The funded work investigates pulmonary neuroendocrine cell (PNEC) biology and the histologic transformation of lung adenocarcinoma to small cell lung cancer. The research employs a genetically engineered...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $671,740 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to define biomarkers and overcome resistance to DLL3-targeting immune therapies in small cell lung cancer. The research focuses on understanding tumor-intrinsic and immune-related mechanisms of response and resistance to delta-like ligand 3 (DLL3)-targeting T-cell engagers, particularly following the FDA approval of...
- The National Cancer Institute awarded $740,346 to The University of Texas MD Anderson Cancer Center on September 9, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393), a Project Grant classified as assistance funding. MD Anderson will develop efficient methods for measuring and characterizing genetic interactions in cancer cells using a CRISPR/Cas12a-based multiplexing system called IN4MER, which quantitates genetic interactions with five-fold fewer reagents than...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $645,186 on August 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop lung cell transplantation therapies for chemotherapy-induced pulmonary fibrosis in cancer patients. The research addresses a significant clinical gap: chemotherapy drugs including bleomycin, methotrexate, and oxaliplatin induce pulmonary fibrosis in cancer patients, and lung transplantation—the only currently...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $825,966 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded September 4, 2025, with a completion date of August 31, 2030. The RISE (Reducing Cancer and HIV Stigma Through Empowerment) project delivers a multilevel, culturally adapted storytelling intervention designed to address dual stigma experienced by Zambian women living with...
- The National Cancer Institute awarded $192,240 to The University of Texas MD Anderson Cancer Center on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop cancer digital twins that optimize treatment stratification for triple-negative breast cancer. The award funds the establishment of cancer digital twin techniques to integrate real-time clinical and multi-modal data into virtual patient models that predict individual patient responses to neoadjuvant...